Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class compound against the RNA modifying enzyme, METTL3.

STORM Therapeutics is a clinical stage biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

This is a significant milestone for the RNA enzyme field, as it will establish if this new area of RNA biology is tractable for therapeutic intervention.

Tony Kouzarides, Director of the Milner Therapeutics Institute and Co-founder of STORM Therapeutics